24. September 2024, 10:00 until 10:00

Johannes Karges, Faculty of Chemistry and Biochemistry, Ruhr-Universität Bochum/Germany

Seminar

Lightning Up Platinum Complexes for Tumor-Targeted Anticancer Therapy

The Platinum(II) complexes cisplatin and its derivatives dominate the field of anticancer chemotherapeutic agents. Despite their clinical success, these compounds are associated with severe side effects (i.e., nerve and kidney damage, nausea, vomiting, bone marrow suppression). To overcome these drawbacks, increasing research efforts are devoted towards Platinum(IV) complexes as prodrugs. These compounds are ideally inactive under physiological conditions but are reduced into their analogous Platinum(II) therapeutically active compounds within the cancerous cells. Typically, the reduction is caused by reducing agents such as glutathione, metallothionein, or ascorbic acid which are present in high levels within cancer cells.[1] However, as these agents are also available in healthy cells, this mechanism of action is associated with poor selectivity and low efficiency. To overcome this limitation, this presentation will focus on the tumor-targeted delivery and selective activation of Platinum(IV) prodrugs with light or ultrasound for anticancer therapy.[2-3] The ability to activate these Platinum(IV) prodrugs on demand allows for an anticancer treatment with high precision and selectivity.

[1] J. Karges, ChemNanoMat 2023, 9, e202300295.
[2] D. Wei, Y. Huang, B. Wang, L. Ma, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2022, 61, e202201486.
[3] G. Liang, T. Sadhukhan, S. Banerjee, D. Tang, H. Zhang, M. Cui, N. Montesdeoca, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2023, 62, e202301074.

Calendar entry

Event location

SEM.R. DB gelb 05 B
1040 Wien
Wiedner Hauptstraße 8-10/E134

 

Organiser

IAP
Manuela Marik
marik@iap.tuwien.ac.at

 

Public

Yes

 

Entrance fee

No

 

Registration required

No